ARWR
Price
$23.95
Change
-$0.58 (-2.36%)
Updated
Dec 8, 6:59 PM EST
60 days until earnings call
CYTK
Price
$34.10
Change
-$0.76 (-2.18%)
Updated
Dec 8, 6:59 PM EST
74 days until earnings call
Ad is loading...

Compare predictions ARWR vs CYTK

Header iconARWR vs CYTK Comparison
Open Charts ARWR vs CYTKBanner chart's image
Arrowhead Pharmaceuticals
Price$23.95
Change-$0.58 (-2.36%)
Volume$435.42K
CapitalizationN/A
Cytokinetics
Price$34.10
Change-$0.76 (-2.18%)
Volume$826.44K
CapitalizationN/A
View a ticker or compare two or three
ARWR vs CYTK Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
ARWR vs. CYTK commentary
Dec 10, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a StrongSell and CYTK is a StrongSell.

COMPARISON
Comparison
Dec 10, 2023
Stock price -- (ARWR: $23.95 vs. CYTK: $34.10)
Brand notoriety: ARWR: Notable vs. CYTK: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 76% vs. CYTK: 99%
Market capitalization -- ARWR: $3.08B vs. CYTK: $3.12B
ARWR [@Biotechnology] is valued at $3.08B. CYTK’s [@Biotechnology] market capitalization is $3.12B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileCYTK’s FA Score has 2 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • CYTK’s FA Score: 2 green, 3 red.
According to our system of comparison, CYTK is a better buy in the long-term than ARWR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 5 TA indicator(s) are bullish while CYTK’s TA Score has 5 bullish TA indicator(s).

  • ARWR’s TA Score: 5 bullish, 5 bearish.
  • CYTK’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than ARWR.

Price Growth

ARWR (@Biotechnology) experienced а +3.37% price change this week, while CYTK (@Biotechnology) price change was +1.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10161.68%. For the same industry, the average monthly price growth was +8.48%, and the average quarterly price growth was +27.10%.

Reported Earning Dates

ARWR is expected to report earnings on Feb 08, 2024.

CYTK is expected to report earnings on Feb 22, 2024.

Industries' Descriptions

@Biotechnology (+10161.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ARWR with price predictions.
OPEN
A.I.dvisor published
a Summary for CYTK with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CYTK($3.12B) and ARWR($3.08B) have the same market capitalization . CYTK YTD gains are higher at: -25.578 vs. ARWR (-40.952). ARWR has higher annual earnings (EBITDA): -161.1M vs. CYTK (-462.64M). CYTK has more cash in the bank: 539M vs. ARWR (452M). ARWR has less debt than CYTK: ARWR (82.7M) vs CYTK (748M). ARWR has higher revenues than CYTK: ARWR (256M) vs CYTK (7.82M).
ARWRCYTKARWR / CYTK
Capitalization3.08B3.12B99%
EBITDA-161.1M-462.64M35%
Gain YTD-40.952-25.578160%
P/E RatioN/AN/A-
Revenue256M7.82M3,276%
Total Cash452M539M84%
Total Debt82.7M748M11%
FUNDAMENTALS RATINGS
ARWR vs CYTK: Fundamental Ratings
ARWR
CYTK
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
7625
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
8574
P/E GROWTH RATING
1..100
21
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARWR's Valuation (94) in the Biotechnology industry is in the same range as CYTK (100). This means that ARWR’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (25) in the Biotechnology industry is somewhat better than the same rating for ARWR (76). This means that CYTK’s stock grew somewhat faster than ARWR’s over the last 12 months.

ARWR's SMR Rating (97) in the Biotechnology industry is in the same range as CYTK (100). This means that ARWR’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Price Growth Rating (74) in the Biotechnology industry is in the same range as ARWR (85). This means that CYTK’s stock grew similarly to ARWR’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is in the same range as ARWR (2). This means that CYTK’s stock grew similarly to ARWR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRCYTK
RSI
ODDS (%)
Bullish Trend 3 days ago
76%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
68%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
74%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
86%
Declines
ODDS (%)
Bearish Trend 25 days ago
81%
Bearish Trend 13 days ago
73%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
81%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CDC56.420.04
+0.07%
VictoryShares US EQ Inc Enh Vol Wtd ETF
RSPR31.29N/A
-0.02%
Invesco S&P 500 Equal Weight Real Estate ETF
IXP72.98-0.03
-0.04%
iShares Global Comm Services ETF
MMSB23.30-0.10
-0.43%
IQ MacKay Multi-Sector Income ETF
PAXS13.99-0.18
-1.27%
PIMCO Access Income Fund

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with ALNY. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-2.36%
ALNY - ARWR
46%
Loosely correlated
-4.07%
AXON - ARWR
46%
Loosely correlated
+0.45%
BEAM - ARWR
44%
Loosely correlated
-8.17%
NTLA - ARWR
42%
Loosely correlated
-2.55%
INVA - ARWR
41%
Loosely correlated
+2.44%
More

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with TVTX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then TVTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
-2.18%
TVTX - CYTK
57%
Loosely correlated
-0.12%
MDGL - CYTK
50%
Loosely correlated
-11.58%
FATE - CYTK
49%
Loosely correlated
-4.68%
REPL - CYTK
47%
Loosely correlated
-4.08%
AGEN - CYTK
45%
Loosely correlated
-7.90%
More